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OBJECTIVE: This study evaluated the diagnostic performance of two methods for the detection of influenza
virus in immunocompromised transplant patients.
METHODS: A total of 475 respiratory samples, 236 from patients in a hematopoietic stem cell transplantation
program and 239 from kidney transplant patients, were analyzed by a direct fluorescence assay and the Centers
for Disease Control real-time polymerase chain reaction protocol for influenza A and B detection.
RESULTS: Influenza detection using either method was 7.6% in the hematopoietic stem cell transplant group
and 30.5% in the kidney transplant patient group. Influenza detection by real-time polymerase chain reaction
yielded a higher positive rate compared with fluorescence than that reported by other studies, and this
difference was more pronounced for influenza A. The fluorescence assay sensitivity, specificity, positive and
negative predictive values, and kappa coefficient were 17.6%, 100%, 1, 0.83, and 0.256, respectively, and lower
detection rates occurred in the kidney transplant patients.
CONCLUSIONS: The real-time polymerase chain reaction performance and the associated turnaround time for a
large number of samples support the choice of this method for use in different routine diagnostic settings and
influenza surveillance in high-risk patients.
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& INTRODUCTION
Laboratory detection of influenza in immunocompromised
patients is crucial for the diagnosis of respiratory illness
because the clinical presentation in these patients is often
nonspecific. Influenza A and B are associated with high
morbidity and mortality in transplant recipients, especially
hematopoietic stem cell transplant (HSCT) patients (1,2).
Kidney transplant (KT) recipients present a high rate of acute
allograft dysfunction when infected with influenza
A(H1N1)pdm09 (3). Although influenza vaccination is
recommended for immunocompromised patients, immuno-
suppressive drugs alter multiple immunological mechanisms,
and those patients may have a poor vaccine response (4).
In recent years, progress has been made in vaccination
strategies and antiviral treatment, but the benefits of this
progress are related to improved diagnostic methods. Several
laboratory techniques are sed in the diagnosis of influenza
virus that differ with respect to sensitivity, cost, and turn-
around time. The direct fluorescence assay (DFA) is com-
monly performed in some medical centers (5) because it can
provide rapid results and has the advantage of detecting
seven respiratory viruses, allowing immediate treatment
decisions to be made. Real-time polymerase chain reaction
(qPCR) has been widely used since the 2009 pandemic and is
the most appropriate method for influenza virus detection due
to its high sensitivity and specificity, rapid turnaround time,
and ability to differentiate seasonal and pandemic strains.
The aim of this study was to evaluate the diagnostic
performance of DFA and qPCR in the detection of influenza
virus infection among immunocompromised transplant
patients.
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& PATIENTS AND METHODS
Study population and specimen collection
This was a retrospective study. The samples included in
this analysis were collected from two groups of patients
treated at Sa˜o Paulo Hospital:
– Kidney transplant group: kidney transplant outpati-
ents with a clinical diagnosis of acute respiratory
illness (ARI) of probable viral etiology were consid-
ered eligible after undergoing physician evaluation at
the renal transplant clinic from July 2002 to December
2004;
– HSCT group: patients with HSCT or hematological
malignancies in the transplant program treated at the
hematology outpatient clinic or hematology ward
from March 2008 to December 2011 were included.
Patients with ARI were included according to pre-
vious evaluation by an infectious disease specialist,
and all samples were submitted for routine diagnosis
by DFA at our laboratory.
ARI was considered if acute symptoms of coryza, sore
throat, or cough, with or without fever, or general
symptoms, including myalgia, chills, and headache, were
reported. Nasal washes were collected using 10 mL of
lactated Ringer’s solution (5 mL/nostril) and transported to
the Clinical Virology Laboratory. DFA was performed
immediately, and an aliquot was frozen at -80 C˚ for further
molecular analysis.
The use of data and all procedures performed in this
study were approved by the Ethics Committee of Sa˜o Paulo
Hospital and the Federal University of Sa˜o Paulo. Written
informed consent was obtained before enrollment. A
questionnaire, which included questions about the presence
of respiratory and general symptoms, time between onset of
symptoms and sample collection, pre-existing conditions,
and comorbidities, was utilized to obtain epidemiological
and clinical data for the study.
Influenza detection
DFA was performed as previously described (6) using the
Simulfluor Respiratory Screen and Panel kit (Chemicon Int.,
USA). Nucleic acid was extracted from 140 mL of aliquots
that had been stored at -80 C˚, using the QIAmp Viral RNA
kit (Qiagen, Germany), according to the manufacturer’s
recommendations. We utilized the CDC qPCR protocol for
influenza A(H1N1)pdm09 (7), with minor modifications
to detect influenza B, using the AgPath-ID TM One Step
RT-PCR kit (Ambion, USA) with a model ABI 7500 system
(Applied Biosystems, USA). The primers used for detection
targeted conserved regions of the matrix gene segment of
influenza A and the non-structural (NS) gene segment of
influenza B (8). RnaseP (a constitutive gene) was used as an
internal control.
Statistical analysis
Statistical analysis was performed using a two-by-two
table in OpenEpi (www.openepi.com), with the diagnostic
qPCR as the gold standard. A chi-square test was conducted
to assess the possible associations between the categorical
variables, with a two-tailed significance level of p,0.05.
& RESULTS
The present study evaluated 475 samples collected from
239 KT patients and 236 samples from the HSCT group. In
the HSCT group, 46% (109/236) were HSCT patients and
54% (127/236) were hematological patients in a HSCT
program. The vaccination rate was 8% (19/239) in the KT
patients and 0.4% (1/236) in the HSCT group. The mean
period between symptom onset and sample collection from
KT patients was longer than that in the HSCT group
(p,0.05). Table 1 provides the epidemiological and clinical
characteristics of the patient groups.
In the KT group, cough was reported by 76.6% of patients,
coryza by 77.8% of patients, and sore throat by 34.3% of
patients. Fever and general symptoms were reported by
only 18.8 and 57.3% of patients, respectively. In the HSCT
group, the frequencies of cough, coryza, and sore throat
were 58.9, 71.2, and 18.2%. Fever was reported by 42.4% of
patients, and general symptoms were reported by 27.5% of
patients.
Overall, 19.1% (91/475) of the samples from the 2 patient
groups were influenza-positive by qPCR, and 3.4% (16/475)
were positive by DFA. A positivity rate of 30.5% (73/239)
was obtained in the KT group, whereas influenza was
detected by any method in 7.6% (18/236) of the patients in
the HSCT group. Influenza was detected in almost all
months, but detection was more frequent during flu season
months. In the HSCT group, influenza occurrence in already
transplanted patients was 12.8% (14/109), and in patients in
the transplant program, the percentage was 3.1% (4/127).
Table 1 shows the comparative results obtained for each
assay according to the patient group.
Seventy-five samples were qPCR-positive but DFA-
negative, and no sample was found to be positive
exclusively by the DFA. DFA sensitivity, specificity, positive







KT patients 239 9 (3.8) 73 (30.5)
Mean age (years) 38.8¡12.8 38.8¡15 38.6¡13.7
Period between symptom onset and collection (days) 11¡11.3 4.3¡4.3 8.3¡9.2
HSCT group 236 7 (3) 18 (7.6)
Autologous transplant 64 5 (7.8) 10 (15.6)
Allogeneic transplant 45 2 (4.4) 4 (8.9)
Hematological malignancies 127 0 4 (3.1)
Mean age (years) 32.5¡15.3 45.7¡14.9 41.4¡15.2
Period between symptom onset and collection (days) 4.3¡5.6 3.7¡1.8 3.5¡1.8
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predictive value (PPV), negative predictive value (NPV) and
kappa coefficient were 17.6%, 100%, 100%, 83.7% and 0.256,
when we used qPCR as gold standard. The low detection of
DFA was observed even in samples collected within a few
days of symptom onset (Figure 1). The duration between
symptom onset and sample collection for samples that tested
positive only by qPCR was, on average, 4 days longer than
that for the DFA-positive samples (8 vs. 4 days), and the mean
cycle threshold (CT) values of the negative and positive
samples according to DFA were 34.4 (range, 20 to 38¡3.6)
and 26.5 (range, 19 to 36¡5.2), respectively (p,0.05).
Among the KT patients, fever was associated with
influenza positivity by DFA (table 2) and qPCR (Table 3).
In the HSCT group, this association was not observed.
In the KT patients, influenza A was detected by qPCR in
26.3% (63/239) of samples and by DFA in 2.1% (5/239) of
samples. Influenza B was detected in 4.2% (10/239) and 1.7%
(4/239) of samples by qPCR and DFA, respectively. In this
group, the influenza A and B positivity rates (by any method),
respectively, according to the years of study, were 60% and
7.5% in 2002, 59% and 0% in 2003, and 13.4% and 4% in 2004.
In the HSCT group, influenza A was detected in 4.7% (11/
236) of samples by qPCR and in 2.5% (6/236) of samples by
DFA. The influenza B positivity rates were 3% (7/236) and
0.4% (1/236), respectively. In this group, the influenza A
and B positivity rates (by any method), respectively, were
4.3% and 6.4% in 2008, 7.8% and 0% in 2009, 0% and 5.9% in
2010, and 2% and 0% in 2011. Influenza A(H1N1)pdm09
was not detected during the study period (2009-2011).
& DISCUSSION
This study compared the efficiency of DFA and qPCR in the
detection of influenza in immunocompromised patients.
Nosocomial outbreaks of influenza are common, and
immunocompromised patients are at significant risk. For the
diagnosis of influenza in these patients, it is necessary to use a
rapid and sensitive test that enables early identification of
influenza cases and facilitates appropriate management deci-
sions, such as patient isolationand antiviral treatment initiation.
The comparison of the methods was conducted using 475
samples collected from KT recipients and patients in a HSCT
program with respiratory infection. We detected influenza in
19.1% of the samples from the two groups of patients, which is
in agreement with other Brazilian studies that have reported
influenza A and B viruses as important causes of respiratory
viral disease in immunocompromised and pediatric patients
(9,10). The incidence of influenza infection among HSCT
recipients is variable and is related to influenza epidemics in
addition to the prevention measures adopted by each center.
Our influenza detection rate in the HSCT group (7.6%) was
lower but similar to that found in other studies (11,12).
Real-time PCR greatly enhanced the accuracy of influenza
detection compared with DFA alone, detecting an addi-
tional 75 positive samples. This difference was higher than
that reported by Kuypers et al. (13), who obtained a four-
fold greater number of positive samples by PCR than by
DFA. Previous studies have demonstrated that qPCR is
particularly efficient for the detection of influenza virus
compared with traditional techniques in samples obtained
more than four days after experimental infection (14).
In our study, a low rate of DFA detection occurred even in
samples collected within a few days of symptom onset.
However, the duration between symptom onset and sample
collection for discordant samples (qPCR+/DFA-) was four
days longer than that for positive DFA samples. As high CT
values are representative of a low viral load, the fact that the
CT values of these discordant samples are higher than those
in DFA-positive samples may be related to a lower viral
load. It has been demonstrated recently that most of the
Figure 1 - Influenza positivity rate according to the time from illness onset to specimen collection.
Table 2 - Univariate logistic regression analysis of the
association between the presence of fever and positivity
by DFA in KT patients.
Variable
DFA +
n (%) p-value OR (95% CI)
No fever
(n = 194)
3 (1.5) 0.0002* 9.79 (2.35-40.85)
Fever (n = 45) 6 (13.3)
OR=odds ratio; CI = confidence interval; * Significant at p,0.05.
Table 3 - Univariate logistic regression analysis of the
association between the presence of fever and positivity
by qPCR in KT patients.
Variable
qPCR +
n (%) p-value OR (95% CI)
No fever (n = 194) 49 (25.2) 0.0002* 3.38 (1.73-6.6)
Fever (n = 45) 24 (53.3)
OR=odds ratio; CI = confidence interval; * Significant at p,0.05.
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respiratory viruses not detected by DFA have low copy
numbers of viral nucleic acid (13). It is important to consider
that viral shedding in immunocompromised patients can
be longer, and viral detection can occur over prolonged
periods.
Differences in the duration between symptom onset and
sample collection, studied periods, and physician suspicion
between the two groups of patients could be responsible for
the lower detection by DFA in KT patients. HSCT patients
are considered to be a group at high risk for complications
arising from respiratory infections, resulting in prompt
clinical examination and sample collection for laboratory
investigation.
Fever was reported by 30.5% of the studied patients and by
only 37% of patients with influenza infection, which confirms
that clinical influenza presentation in immunocompromised
patients may be atypical due to medications that modulate
the inflammatory response (15). Nevertheless, the presence of
fever was strongly associated with influenza detection by any
method.
We had the highest positivity rate in HSCT group (7.8%)
in 2009. These cases were detected before the influenza
pandemic; thus, none of the cases were typed as
A(H1N1)pdm09. After the announcement of the pandemic
in Brazil, our center adopted rigorous control measures to
prevent nosocomial infection and its consequent impact in
high-risk patients. Previous studies have demonstrated the
effectiveness of isolation of suspected cases, use of masks
and gloves in the HSCT unit, and respiratory virus testing of
symptomatic patients (2,16).
In conclusion, the labor-intensive nature of the DFA, the
need for highly trained technical personnel to perform the
assay, and the low sensitivity of the assay have reduced its
utility. Alternatively, the performance and turnaround time
of qPCR when analyzing a higher number of samples support
the choice of this method for different routine diagnostic
settings and influenza surveillance in high-risk patients.
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